<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><description>医药行业一致性评价工作在如火如荼的进行中，作为行业的一份子，愿本愚公之念，出蝼蚁 之力，献寸光之策。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 23 Feb 2021 23:21:50 +0800</pubDate><image><url>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</url><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>年销超35亿的重磅注射剂，离集采之路还有多远？</title><link>https://mp.weixin.qq.com/s/A-dzlgINRc2elwnI4aoh9A</link><description></description><content:encoded><![CDATA[年销超35亿的重磅注射剂，离集采之路还有多远？]]></content:encoded><pubDate>Tue, 23 Feb 2021 21:38:27 +0800</pubDate></item><item><title>单品种上亿的市场，这款哮喘病-手性药物有望接力！</title><link>https://mp.weixin.qq.com/s/MCrWf5MTEOxWwYWHV7iPZQ</link><description></description><content:encoded><![CDATA[单品种上亿的市场，这款哮喘病-手性药物有望接力！]]></content:encoded><pubDate>Tue, 23 Feb 2021 21:38:27 +0800</pubDate></item><item><title>CDE：技术审评报告工作规范（试行），提及“商业秘密”部分</title><link>https://mp.weixin.qq.com/s/yBVljHiKQAC6g4yR5AXnvQ</link><description></description><content:encoded><![CDATA[CDE：技术审评报告工作规范（试行），提及“商业秘密”部分]]></content:encoded><pubDate>Tue, 23 Feb 2021 21:38:27 +0800</pubDate></item><item><title>第四批国采，最新执行通知发布！</title><link>https://mp.weixin.qq.com/s/PnfhVnsgL_gdRjvuBtpogw</link><description></description><content:encoded><![CDATA[第四批国采，最新执行通知发布！]]></content:encoded><pubDate>Tue, 23 Feb 2021 21:38:27 +0800</pubDate></item><item><title>这批药品降价了</title><link>https://mp.weixin.qq.com/s/OyuKXU1KcHq3ikpHDgpGEQ</link><description></description><content:encoded><![CDATA[这批药品降价了]]></content:encoded><pubDate>Tue, 23 Feb 2021 21:38:27 +0800</pubDate></item><item><title>无专利限制，高技术壁垒...曲普瑞林-机遇与挑战并存</title><link>https://mp.weixin.qq.com/s/W_IuWZtdf1w4gTrIGVmFzQ</link><description></description><content:encoded><![CDATA[无专利限制，高技术壁垒...曲普瑞林-机遇与挑战并存]]></content:encoded><pubDate>Mon, 22 Feb 2021 21:36:58 +0800</pubDate></item><item><title>知名大三甲：这些药品短缺，直接挂网（附最新中标价）</title><link>https://mp.weixin.qq.com/s/3imDPF6SChL7JlAPR4dp0A</link><description></description><content:encoded><![CDATA[知名大三甲：这些药品短缺，直接挂网（附最新中标价）]]></content:encoded><pubDate>Mon, 22 Feb 2021 21:36:58 +0800</pubDate></item><item><title>「4+7」第二年续约期到来...</title><link>https://mp.weixin.qq.com/s/9isGKrYPfmDdqCc0sbRuyw</link><description></description><content:encoded><![CDATA[「4+7」第二年续约期到来...]]></content:encoded><pubDate>Mon, 22 Feb 2021 21:36:58 +0800</pubDate></item><item><title>第五批国采，随即赶到？！</title><link>https://mp.weixin.qq.com/s/489AVJA863Wbpy10WGTfhg</link><description></description><content:encoded><![CDATA[第五批国采，随即赶到？！]]></content:encoded><pubDate>Mon, 22 Feb 2021 21:36:58 +0800</pubDate></item><item><title>引进日本产品或开拓日本市场，它能帮你！</title><link>https://mp.weixin.qq.com/s/veiwaAv0jDUUOiuVazOinQ</link><description></description><content:encoded><![CDATA[引进日本产品或开拓日本市场，它能帮你！]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:32:44 +0800</pubDate></item><item><title>12亿日元转让！一家集批发零售+自主品牌的日本药企</title><link>https://mp.weixin.qq.com/s/KV31qE4Shzz9GhYAfJMAHA</link><description></description><content:encoded><![CDATA[12亿日元转让！一家集批发零售+自主品牌的日本药企]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:32:44 +0800</pubDate></item><item><title>2020年全球畅销药Top 5，合计大卖650亿美元！</title><link>https://mp.weixin.qq.com/s/-SSjQy2JIaAxBRZpz9Ot5A</link><description></description><content:encoded><![CDATA[2020年全球畅销药Top 5，合计大卖650亿美元！]]></content:encoded><pubDate>Sat, 20 Feb 2021 21:40:52 +0800</pubDate></item><item><title>50亿抗肿瘤注射液，齐鲁、扬子江、天晴同日拿下！</title><link>https://mp.weixin.qq.com/s/UxRKlJOTgWY_E2xQG0INyQ</link><description></description><content:encoded><![CDATA[50亿抗肿瘤注射液，齐鲁、扬子江、天晴同日拿下！]]></content:encoded><pubDate>Sat, 20 Feb 2021 21:40:52 +0800</pubDate></item><item><title>CDE：第一批拟不推荐参比品种药学研究公开征求意见</title><link>https://mp.weixin.qq.com/s/Iff2zg9Nn50ezgRyekkcYA</link><description></description><content:encoded><![CDATA[CDE：第一批拟不推荐参比品种药学研究公开征求意见]]></content:encoded><pubDate>Sat, 20 Feb 2021 21:40:52 +0800</pubDate></item><item><title>63个临床短缺药，直接挂网采购</title><link>https://mp.weixin.qq.com/s/Nd_w8k0HKQ2L7hvWVs7OEQ</link><description></description><content:encoded><![CDATA[63个临床短缺药，直接挂网采购]]></content:encoded><pubDate>Sat, 20 Feb 2021 21:40:52 +0800</pubDate></item><item><title>（2021.2.19）最新过评名单，3品种首家冲线！</title><link>https://mp.weixin.qq.com/s/M2w7UbNbwsYT85skZDPplg</link><description></description><content:encoded><![CDATA[（2021.2.19）最新过评名单，3品种首家冲线！]]></content:encoded><pubDate>Fri, 19 Feb 2021 21:39:45 +0800</pubDate></item><item><title>新版医保执行在即，都有哪些品种入围？</title><link>https://mp.weixin.qq.com/s/a-oeAaOIBaunWngS7C7tDQ</link><description></description><content:encoded><![CDATA[新版医保执行在即，都有哪些品种入围？]]></content:encoded><pubDate>Fri, 19 Feb 2021 21:39:45 +0800</pubDate></item><item><title>3款抗癌药价格下调</title><link>https://mp.weixin.qq.com/s/fnv6vaFmusuDDLq0tPCrNg</link><description></description><content:encoded><![CDATA[3款抗癌药价格下调]]></content:encoded><pubDate>Fri, 19 Feb 2021 21:39:45 +0800</pubDate></item><item><title>一致性评价，“扩容”了...</title><link>https://mp.weixin.qq.com/s/nSes-YzG2UxGvUDj_i9BrQ</link><description></description><content:encoded><![CDATA[一致性评价，“扩容”了...]]></content:encoded><pubDate>Fri, 19 Feb 2021 21:39:45 +0800</pubDate></item><item><title>原料药，国内的好找，国外的怎么找？</title><link>https://mp.weixin.qq.com/s/D1ck0546AhP4VB1rKTM96w</link><description></description><content:encoded><![CDATA[原料药，国内的好找，国外的怎么找？]]></content:encoded><pubDate>Thu, 18 Feb 2021 21:49:08 +0800</pubDate></item></channel></rss>